Procedure time reduction in lithotripsy and benefits in BPH
treatments
YOKNEAM, Israel, March 15, 2019 /PRNewswire/ -- Lumenis Ltd.,
the world's largest energy-based medical device company for
surgical, aesthetic and ophthalmic applications, announces the
release of new clinical evidence and advantages in lithotripsy and
benign prostatic hyperplasia (BPH) treatments using the
MOSES™ Technology at the 34th annual European
Association of Urology Congress (EAU19), taking place in
Barcelona, March 15-19, 2019.
For the last 30 years, holmium lasers and fibers have been
clinically proven as the gold-standard modality for the treatment
of urinary stones and BPH. Released by Lumenis two years ago, MOSES
is a revolutionary, patent-protected technology. MOSES
utilizes a proprietary combination of holmium lasers and fibers
that optimize holmium energy transmission using a unique pulse
modulation. Significant clinical evidence highlighting the benefits
of MOSES in lithotripsy has already been released, demonstrating
that lithotripsy procedures conducted with the MOSES technology
result in 20% faster procedures, 25% more efficient fragmentation,
and 60% reduction in stone retropulsion.
The advantages of MOSES for lithotripsy and BPH procedures are
being researched and demonstrated by leading academic institutions
worldwide. In BPH procedures, clinical evaluations are ongoing and
focused on studying advantages in enucleation of the prostate,
including smoother incision, better hemostasis and shorter
procedure time. In lithotripsy, the advantages of MOSES are studied
across a number of procedures and techniques including Mini PCNL,
Ultra Mini PCNL, Flexible Ureteroscopy and RIRS. These advantages
will be presented in a series of poster and video sessions by
leading worldwide key opinion leaders including:
- Dr. Khurshid
Ghani of the University of
Michigan, Ann Arbor (USA) -
Impact of variable pulse width and pulse modulation on dusting
effect for holmium laser lithotripsy: In vitro evaluation with
calcium oxalate monohydrate stones
- Dr. Oriol Angerri of Fundacio Puigvert,
Barcelona (Spain) - High-power holmium laser lithotripsy
with MOSES Technology – initial experience
- Prof. Thomas
Knoll of Klinikverbund-Sudwest, Sindelfingen
(Germany) - Miniaturized
percutaneous nephrolithotomy with MOSES laser
lithotripsy
MOSES will also take center stage during the EAU live surgery
plenary session:
- Dr. Karin Lehrich of
Vivantes Auguste-Victioria Hospital, Berlin (Germany) – MOSES Holmium Laser Enucleation of
the Prostate (HoLEP) for BPH
- Dr. Michael
Lipkin of Duke
University, Durham (USA) –
MOSES Bladder stone lithotripsy
- Dr. Oriol Angerri of Fundacio Puigvert,
Barcelona (Spain) – MOSES MiniPCNL
- Dr. Esteban
Emiliani of Fundacio Puigvert, Barcelona (Spain) – Flexible Ureteroscopy with the MOSES
Technology
"Just two years since the launch of our patented MOSES
Technology, it brings us tremendous pride to see the urology
community actively researching and discovering its benefits for a
wide range of urology procedures," said Tzipi Ozer-Armon, CEO of Lumenis. "We are
excited to be at the forefront of urology care and part of this
continuous improvement in patient outcomes, and we are committed to
continuing the development of MOSES in a multitude of clinical
applications"
During EAU19, attendees will be able to get a first-hand
experience of the technology in the 360 degree simulation lab
at the Lumenis booth I-26.
About Lumenis
www.lumenis.com
Lumenis is the world's largest energy-based medical device
company for surgical, aesthetic and ophthalmic applications in the
area of minimally invasive clinical solutions. Regarded as a
world-renowned expert in developing and commercializing innovative
energy-based technologies, including Laser, Intense Pulsed Light
(IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis'
ground-breaking products have redefined medical treatments and have
set numerous technological and clinical gold-standards. Lumenis has
successfully created solutions for previously untreatable
conditions, as well as designed advanced technologies that have
revolutionized existing treatment methods.
MEDIA CONTACT
Genevieve Britton
genevieve@pascalecommunications.com
Photo - https://mma.prnewswire.com/media/836129/Lumenis.jpg
Logo - https://mma.prnewswire.com/media/541530/Lumenis_Logo.jpg